by Say Tung Kun. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1998. / Includes bibliographical references (leaves 80-92). / Abstract also in Chinese. / Title --- p.i / Table of Contents --- p.ii / List of tables --- p.vi / List of abbreviations --- p.viii / Acknowledgements --- p.xi / Abstract --- p.xii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- Lipids: their nature and function in man --- p.1 / Chapter 1.2 --- Lipid metabolism --- p.2 / Chapter 1.3 --- The definition and classification of hyperlipidaemia --- p.3 / Chapter 1.3.1 --- The definition of hyperlipidaemia --- p.3 / Chapter 1.3.2 --- Lipid levels and diet in Hong Kong and other Chinese populations --- p.5 / Chapter 1.3.3 --- The classification of hyperlipidaemia --- p.8 / Chapter 1.3.4 --- The primary hyperlipidaemias: Genetic disorders of lipid metabolism --- p.8 / Chapter 1.3.5 --- The secondary causes of hyperlipidaemia --- p.8 / Chapter 1.4 --- The signs and symptoms of hyperlipidaemia --- p.10 / Chapter 1.4.1 --- The signs of hyperlipidaemia --- p.10 / Chapter 1.4.1.1 --- Corneal arcus --- p.10 / Chapter 1.4.1.2 --- Xanthomata --- p.11 / Chapter 1.4.1.3 --- Xanthelasmata --- p.11 / Chapter 1.4.2 --- The symptoms of hyperlipidaemia --- p.12 / Chapter 1.5 --- The investigations and monitoring of hyperlipidaemia during studies of drug treatment --- p.12 / Chapter 1.5.1 --- The clinical investigation of hyperlipidaemia --- p.12 / Chapter 1.5.2 --- The clinical and laboratory monitoring of hyperlipidaemia --- p.13 / Chapter 1.5.2.1 --- The clinical monitoring of hyperlipidaemia --- p.13 / Chapter 1.5.2.2 --- The laboratory monitoring of hyerlipidaemia --- p.13 / Chapter 1.6 --- The therapy of hyperlipidaemia --- p.13 / Chapter 1.6.1 --- The response to lipid-lowering drug therapy --- p.14 / Chapter 1.6.1.1 --- The response to the flbric acid derivatives --- p.15 / Chapter 1.6.2 --- Detection of hyperlipidaemia and benefits of treatment --- p.19 / Chapter 1.6.3 --- The significance of the present studies --- p.21 / Chapter Chapter 2 --- Hyperlipidaemia: relationship to other diseases --- p.23 / Chapter 2.1 --- Atherosclerosis --- p.23 / Chapter 2.2 --- Vascular Insufficiency Diseases --- p.24 / Chapter 2.3 --- Hypertension --- p.25 / Chapter 2.4 --- Diabetes mellitus --- p.26 / Chapter 2.5 --- Thyroid disorders --- p.30 / Chapter 2.6 --- Liver disease --- p.31 / Chapter 2.7 --- Pancreatitis --- p.32 / Chapter 2.8 --- Renal disease --- p.32 / Chapter 2.8.1 --- Nephrotic syndrome --- p.32 / Chapter 2.8.2 --- Chronic renal failure --- p.33 / Chapter 2.8.3 --- Renal transplant patients --- p.33 / Chapter Chapter 3 --- Patients and methods in the lipid studies --- p.34 / Chapter 3.1 --- Characteristics of patients with hypertriglyceridaemia in Hong Kong --- p.34 / Chapter 3.2 --- Clinical and laboratory methods to measure the response to drug treatment --- p.37 / Chapter 3.2.1 --- Clinical methods to assess the response to drug treatment --- p.37 / Chapter 3.2.1.1 --- History --- p.37 / Chapter 3.2.1.2 --- Physical examination --- p.38 / Chapter 3.2.1.3 --- Clinical measurement --- p.39 / Chapter 3.3 --- The laboratory methods to measure the lipid response to drug treatment --- p.39 / Chapter 3.2.1 --- The methodology for the extended lipid profile --- p.40 / Chapter 3.3.2 --- Statistical analysis --- p.41 / Chapter Chapter 4 --- Gemfibrozil dose-response study --- p.43 / Chapter 4.1 --- Dose-response study of gemfibrozil in Chinese patients with combined hyperlipidaemia --- p.43 / Chapter 4.1.1 --- Introduction --- p.43 / Chapter 4.1.2 --- Patients --- p.44 / Chapter 4.1.3 --- Results --- p.45 / Chapter 4.1.4 --- Discussion --- p.51 / Chapter Chapter 5 --- Gemfibrozil 900 mg tablet study --- p.53 / Chapter 5.1 --- Assessment of the efficacy and tolerability of a new formulation of gemfibrozil as a 900 mg tablet in the treatment of hyperlipidaemia --- p.53 / Chapter 5.2 --- Patients recruited --- p.53 / Chapter 5.3 --- Methods --- p.54 / Chapter 5.4 --- Results --- p.54 / Chapter 5.4.1 --- Tolerability --- p.54 / Chapter 5.4.2 --- Efficacy --- p.55 / Chapter 5.5 --- Discussion --- p.61 / Chapter Chapter 6 --- Bezafibrate study --- p.64 / Chapter 6.1 --- Assessment of the efficacy and tolerability of bezafibrate in the treatment of hyperlipidaemia --- p.64 / Chapter 6.2 --- Introduction --- p.64 / Chapter 6.3 --- Patients --- p.65 / Chapter 6.4 --- Results of bezafibrate study --- p.66 / Chapter 6.4.1. --- Tolerability --- p.66 / Chapter 6.4.2. --- Efficacy --- p.66 / Chapter 6.5. --- Discussion --- p.73 / Chapter Chapter 7 --- Discussion and Conclusions --- p.75 / Chapter 7.1 --- "Introduction: the two study drugs, gemfibrozil and bezafibrate" --- p.75 / Chapter 7.2 --- Gemfibrozil --- p.76 / Chapter 7.3 --- Bezafibrate --- p.77 / Chapter 7.4 --- Conclusion --- p.78 / References --- p.80 / Appendix I. Abstracts relating to these studies from presentations at national and international meetings --- p.93 / Appendix II. Side effect questionnaire used in the studies --- p.95
| Identifer | oai:union.ndltd.org:cuhk.edu.hk/oai:cuhk-dr:cuhk_322515 |
| Date | January 1998 |
| Contributors | Say, Tung Kun., Chinese University of Hong Kong Graduate School. Division of Medical Sciences. |
| Source Sets | The Chinese University of Hong Kong |
| Language | English, Chinese |
| Detected Language | English |
| Type | Text, bibliography |
| Format | print, xiii, 96 leaves ; 30 cm. |
| Rights | Use of this resource is governed by the terms and conditions of the Creative Commons “Attribution-NonCommercial-NoDerivatives 4.0 International” License (http://creativecommons.org/licenses/by-nc-nd/4.0/) |
Page generated in 0.002 seconds